Nelarabine

General Information

Nelarabine Impurities and Nelarabine  

Daicel Pharma is a trusted provider of quality Nelarabine impurity standards, including 2,6-Diaminopurine arabinoside, 9-(Beta-d-arabino furanosyl) Guanine, Nelarabine Alpha isomer impurity, Nelarabine impurity 17, and Nelarabine Stage-1 Impurity. These impurities are critical in determining the active pharmaceutical ingredient Nelarabine’s quality, stability, and biological safety. Additionally, Daicel Pharma can synthesize Nelarabine impurities according to precise customer specifications while guaranteeing worldwide delivery.

Nelarabine [CAS: 121032-29-9] is a pro-drug of the deoxyguanosine analog, 9-β-Darabinofuranosylguanine (ara-G). It treats patients diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not shown a response to or have experienced a relapse after undergoing at least two chemotherapy regimens.

Nelarabine: Use and Commercial Availability   

Nelarabine treats T-cell acute lymphoblastic leukemia, a rare type of non-Hodgkin lymphoma primarily affecting lymph nodes. It is for patients who have not responded to or have relapsed following treatment with at least two chemotherapy regimens. Nelarabine helps in targeting and killing these cancer cells.

Nelarabine is available under the brand name, Arranon active ingredient Nelarabine.

Nelarabine Structure and Mechanism of Action

The chemical name of Nelarabine is 9-β-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine. Its chemical formula is C₁₁H₁₅N₅O₅, and its molecular weight is approximately 297.27 g/mol.

Nelarabine is converted to the active 5’-triphosphate, ara-GTP, after demethylation by adenosine deaminase (ADA). Nelarabine inhibits DNA synthesis and cell death after ara-GTP accumulation in leukemic blasts.

Nelarabine Impurities and Synthesis

Nelarabine impurities can arise during synthesis¹ due to the storage or use of specific raw materials and intermediates in manufacturing. These impurities encompass related compounds, degradation products, and process impurities. Stringent quality control measures and analytical methods are crucial to ensure the purity and safety of Nelarabine for patient use.

Daicel Pharma provides a comprehensive Certificate of Analysis (CoA) for Nelarabine impurity standards, such as 2,6-Diaminopurine arabinoside, 9-(Beta-d-arabino furanosyl) Guanine, Nelarabine Alpha isomer impurity, Nelarabine impurity 17, and Nelarabine Stage-1 Impurity. The CoA includes detailed characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity². Additionally, upon delivery, a complete 13C-DEPT is also provided. Daicel Pharma possesses the technology and expertise to synthesize any unknown Nelarabine impurity or degradation product.